Veradermics to Hold Conference Call to Discuss 12-Month Long-Term Results from Phase 3 ‘302’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
Veradermics (NYSE: MANE) announced it will host an investor call and webcast on November 9, 2026, at 8:00 am ET to review 12-month topline results from Part B of its Phase 3 Study '302'. The trial evaluates VDPHL01, an extended-release oral minoxidil formulation, in over 500 males with mild-to-moderate pattern hair loss.
Key figures
- Call date
- Monday, November 9, 2026, at 8:00 am ET
- Trial enrollment
- over 500 males
- Patent expiration
- 2043
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.